CPT code 80162 denotes a quantitative laboratory assay measuring total digoxin concentration in blood. This test supports clinical management of patients receiving digoxin for congestive heart failure or rate control, helping clinicians identify therapeutic levels and potential toxicity. Nationally, therapeutic drug monitoring codes like 80162 are important for patient safety, medication optimization, and lab reimbursement pathways.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for digoxin monitoring, common sites where the service is performed, and which payers typically cover such laboratory services. The publication also summarizes benchmark elements relevant to lab billing and reimbursement, highlights coding and billing considerations tied to quantitative drug assays, and outlines implications for clinical workflows and laboratory operations.

This summary is designed for clinicians, laboratory managers, and billing professionals seeking a concise national perspective on CPT code 80162, including clinical rationale, payer scope, and what to expect in terms of service delivery and documentation requirements. Data not available in the input is noted where applicable.